Maiti A, Cortes JE, Patel KP, et al. - Researchers sought to present the long-term follow-up from the first study employing dasatinib as initial therapy for chronic-phase chronic myeloid leukemia. From November 2005 to August 2014, patients were randomized to receive dasatinib 100 mg once daily or 50 mg twice daily, initially. Outcomes suggest that in early chronic myeloid leukemia (CML) in the chronic phase, frontline dasatinib has an outstanding long-term safety profile. Low rates of discontinuation owing to toxicity or disease progression were observed. Dasatinib offers faster cytogenetic responses and deeper molecular responses that are durable over time. With the termination of the DASISION study (Dasatinib vs Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia), this report was identified to be the largest and longest follow-up providing long-term data on the efficacy and safety to guide dasatinib therapy in CML.